Self Administration of Subcutaneous Depot Medroxyprogesterone Acetate: A Pilot Observational Study of Feasibility and Acceptability
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Patient satisfaction with/feasibility of self injection of subcutaneous depot medroxyprogesterone acetate
研究概览
简要总结
The purpose of this study is to assess continuation rates and patient satisfaction with self administration subcutaneous depot medroxyprogesterone acetate.
详细描述
This observational study will include new or current Depo Provera users who express interest in attempting subcutaneous self administration of depot medroxyprogesterone acetate. Candidates will be taught self administration by a clinic assistant at Planned Parenthood of Southwest and Central Florida. Patients who are able to correctly self administer the medication and wish to attempt to continue home self administration, will be provided the supplies and educational materials to do so. Continuation rates and satisfaction with this method will be assessed using preaddressed surveys that patients will return with the above information.
研究设计
- 研究类型
- Observational
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Women 18 years or older
- •Can understand written and spoken English
- •Current or past user of DMPA or desires initiation of DMPA for contraception
- •Provider has approved DMPA use in this woman
- •Willing to consider/attempt DMPA self-injection.
- •Willing to receive phone calls/letter for follow up
- •Willing to return letters for follow up
排除标准
- •Has contraindications to DMPA use:
- •Vaginal bleeding of unknown etiology
- •Medication use for Cushing's syndrome
- •Currently pregnant
- •Blood pressure >160/100
- •Intolerance to the idea of irregular or absent menses
结局指标
主要结局
Patient satisfaction with/feasibility of self injection of subcutaneous depot medroxyprogesterone acetate
时间窗: At onset of trial and every 12 weeks for 1 year
次要结局
- Continuation rates of depot medroxyprogesterone acetate among self-injectors(Every 12 weeks for 1 year)